Key Takeaways
- • Dentons' Paris office advised Bpifrance Large Venture on an oversubscribed US$75 million Series C funding round for Danish biotech company Acendo ApS, demonstrating strong investor demand for the company's clinical-stage pipeline.
- • The financing was oversubscribed, attracting four new institutional investors (Jeito Capital, Vida Ventures, Bpifrance Large Venture, and EIFO) alongside participation from 13 existing backers including major life sciences investors RA Capital Management, TPG, Orbimed, and Novo Holdings.
- • Capital will fund advancement of Acendo's first- and best-in-class antibody-drug conjugate (ADC) programs through multiple upcoming clinical milestones, positioning the company to progress its oncology-focused pipeline.
- • The round represents significant momentum in the ADC therapeutic space, with a broadly syndicated investor base spanning European venture firms, global healthcare specialists, and diversified alternative asset managers.
Summary
Dentons' Paris office successfully advised French public investment bank Bpifrance Large Venture on a US$75 million Series C financing for Acendo ApS, a Danish-headquartered biotech company focused on antibody-drug conjugate (ADC) therapeutics. The round was oversubscribed, reflecting strong institutional appetite for the company's clinical advancement strategy and pipeline potential. The financing closes on April 17, 2026.
The investment syndicate expanded to include four new institutional participants: Jeito Capital, Vida Ventures, Bpifrance Large Venture, and EIFO. Notably, all existing investors participated in the follow-on round, signaling continued confidence in the company's execution trajectory. The existing investor base represents a blue-chip roster of specialized life sciences and diversified investment platforms, including RA Capital Management, TPG, Orbimed, Venrock, TCGX, Novo Holdings, Surveyor, Logos Capital, Pontifax Venture Capital, HealthCap, Gilde Healthcare, Ysios Capital, and Dawn Biopharma (a KKR-controlled platform).
The capital will directly support Acendo's advancement of its ADC pipeline—a therapeutic class targeting oncology indications with increasingly differentiated commercial potential—through key upcoming clinical milestones. ADCs represent a growing category within precision oncology and continue to attract substantial institutional capital as regulatory pathways mature and early clinical data support the mechanism.
The financing composition—mixing European venture capital (Bpifrance, EIFO), specialized life sciences investors (Vida Ventures, RA Capital), and generalist alternatives platforms (TPG, KKR's Dawn Biopharma)—underscores both the geographic breadth and thematic concentration of biotech capital across institutional markets. Dentons' advisory role reflects the firm's established position in cross-border life sciences transactions.
The investment syndicate expanded to include four new institutional participants: Jeito Capital, Vida Ventures, Bpifrance Large Venture, and EIFO. Notably, all existing investors participated in the follow-on round, signaling continued confidence in the company's execution trajectory. The existing investor base represents a blue-chip roster of specialized life sciences and diversified investment platforms, including RA Capital Management, TPG, Orbimed, Venrock, TCGX, Novo Holdings, Surveyor, Logos Capital, Pontifax Venture Capital, HealthCap, Gilde Healthcare, Ysios Capital, and Dawn Biopharma (a KKR-controlled platform).
The capital will directly support Acendo's advancement of its ADC pipeline—a therapeutic class targeting oncology indications with increasingly differentiated commercial potential—through key upcoming clinical milestones. ADCs represent a growing category within precision oncology and continue to attract substantial institutional capital as regulatory pathways mature and early clinical data support the mechanism.
The financing composition—mixing European venture capital (Bpifrance, EIFO), specialized life sciences investors (Vida Ventures, RA Capital), and generalist alternatives platforms (TPG, KKR's Dawn Biopharma)—underscores both the geographic breadth and thematic concentration of biotech capital across institutional markets. Dentons' advisory role reflects the firm's established position in cross-border life sciences transactions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.